Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 27, 2017 (Event Date: July 28, 2017)
Context: The Company entered into a material definitive agreement to conduct a public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 21,500,000 shares of Common Stock and warrants to purchase 18,275,000 shares of Common Stock.
- Offering Price: $0.75 per share and related warrant (public price).
- Underwriting Price: $0.705 per share and related warrant (price paid by underwriters).
- Warrant Terms: Exercisable at $1.05 per share; exercisable for five years from issuance.
- Expected Net Proceeds: Approximately $15 million (after underwriting discounts and estimated offering expenses).
- Expected Closing Date: August 2, 2017.
- Underwriter: Oppenheimer & Co. Inc. (as representative).
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company.
Material Changes
The primary material change is the execution of an underwriting agreement for a significant equity raise. This transaction represents a dilution of existing shareholders through the issuance of new shares and warrants. The filing does not provide comparative financial data to quantify changes in operating metrics versus prior periods.
Guidance, Outlook, and Risks
- Management Commentary: The Company intends to use the net proceeds to fund its operations and clinical development programs, though specific allocation details are not provided in this summary text.
- Lock-Up Agreement: The Company, its directors, and officers agreed not to sell or dispose of Company securities for 90 days following the final prospectus supplement date, subject to exceptions and written consent.
- Risks and Contingencies: The closing of the offering is subject to the satisfaction of customary closing conditions. The Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected August 2, 2017) and confirm if customary conditions were met.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific termination rights and indemnification details.
- Confirm the exact net proceeds received after finalizing all offering expenses.
- Monitor the Company's use of proceeds to ensure alignment with stated operational and clinical development goals.
- Check subsequent filings for any adjustments to the warrant exercise price or terms.